Prostate Cancer Death Linked With Shorter Sleep Duration

Video

This video examines results of a study that found that shorter sleep duration was linked with an increased risk of death among patients with prostate cancer.

In this video, Susan M. Gapstur, PhD, MPH, of the American Cancer Society in Atlanta, discusses an analysis of two large, long-term cohort studies-Cancer Prevention Study-I and Cancer Prevention Study-II-that found that sleep duration was linked with an increased risk of death among patients with prostate cancer.

Results of the study were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

The biological mechanism behind this association is unclear, but research has shown that lack of sleep and the presence of light at night can affect melatonin production, and that low melatonin production can lead to an increase in genetic mutations and can limit DNA repair.

Recent Videos
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content